NL190553C - Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat. - Google Patents

Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat.

Info

Publication number
NL190553C
NL190553C NLAANVRAGE7908192,A NL7908192A NL190553C NL 190553 C NL190553 C NL 190553C NL 7908192 A NL7908192 A NL 7908192A NL 190553 C NL190553 C NL 190553C
Authority
NL
Netherlands
Prior art keywords
aminopirimidines
imidazolin
substituted
compounds
well
Prior art date
Application number
NLAANVRAGE7908192,A
Other languages
English (en)
Dutch (nl)
Other versions
NL7908192A (nl
NL190553B (nl
Original Assignee
Beiersdorf Lilly Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2849537A external-priority patent/DE2849537C2/de
Priority claimed from DE19792937023 external-priority patent/DE2937023A1/de
Application filed by Beiersdorf Lilly Gmbh filed Critical Beiersdorf Lilly Gmbh
Publication of NL7908192A publication Critical patent/NL7908192A/nl
Publication of NL190553B publication Critical patent/NL190553B/xx
Application granted granted Critical
Publication of NL190553C publication Critical patent/NL190553C/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NLAANVRAGE7908192,A 1978-11-15 1979-11-08 Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat. NL190553C (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2849537A DE2849537C2 (de) 1978-11-15 1978-11-15 Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2849537 1978-11-15
DE2937023 1979-09-13
DE19792937023 DE2937023A1 (de) 1979-09-13 1979-09-13 Neue substituierte 5-(2-imidazolin-2-yl)-aminopyrimidine und verfahren zu deren herstellung

Publications (3)

Publication Number Publication Date
NL7908192A NL7908192A (nl) 1980-05-19
NL190553B NL190553B (nl) 1993-11-16
NL190553C true NL190553C (nl) 1994-04-18

Family

ID=25776489

Family Applications (2)

Application Number Title Priority Date Filing Date
NLAANVRAGE7908192,A NL190553C (nl) 1978-11-15 1979-11-08 Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat.
NL940011C NL940011I2 (nl) 1978-11-15 1994-06-27 Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL940011C NL940011I2 (nl) 1978-11-15 1994-06-27 Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat.

Country Status (12)

Country Link
US (1) US4323570A (da)
AT (1) AT374197B (da)
AU (1) AU541305B1 (da)
CA (1) CA1138454A (da)
CH (1) CH642965A5 (da)
DK (1) DK150142C (da)
ES (1) ES486349A1 (da)
FR (1) FR2441625A1 (da)
GB (1) GB2039275B (da)
IT (1) IT1127225B (da)
NL (2) NL190553C (da)
SE (1) SE440079B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2146986B (en) * 1983-09-23 1987-06-17 Lilly Co Eli Process for preparing 5-substituted pyrimidines
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
US5972948A (en) * 1994-07-01 1999-10-26 Solvay Pharmaceuticals Gmbh Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
CA2256720A1 (en) * 1996-06-06 1997-12-11 John Leeper Mcnay Jr. Formulation and method for treating congestive heart failure
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
CA2269971A1 (en) * 1997-09-03 1999-03-11 Trent Lee Abraham Pyrimidine derivatives
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
WO2004000312A2 (de) * 2002-06-19 2003-12-31 Solvay Pharmaceuticals Gmbh Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
KR20080090546A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Cns 장애 치료용 2-이미다졸의 용도
EP1894926A1 (en) * 2006-06-26 2008-03-05 Chemagis Ltd. Polymorphs of moxonidine and processes for preparation therefor
ES2369113T3 (es) 2006-06-26 2011-11-25 Chemagis Ltd. Procedimiento mejorado para producir moxonidina.
ES2315967T3 (es) * 2006-06-26 2009-04-01 Chemagis Ltd. Nuevo procedimiento de purificacion de moxonidina.
WO2008020425A1 (en) * 2006-08-17 2008-02-21 Chemagis Ltd. Crystalline moxonidine comprising single tautomer and preparation process therefor
ATE487712T1 (de) * 2006-08-31 2010-11-15 Chemagis Ltd Verwendung der monoxidinssalze zur reinigung von monoxidin
WO2008046757A1 (en) * 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
DE602007005671D1 (de) * 2006-10-19 2010-05-12 Hoffmann La Roche Aminomethyl-2-imidazole mit affinität zu mit dem trace-amin assoziierten rezeptoren
KR101176700B1 (ko) * 2006-11-02 2012-08-23 에프. 호프만-라 로슈 아게 미량 아민 결합된 수용체의 조절자로서 치환된 2-이미다졸
JP2010510184A (ja) * 2006-11-16 2010-04-02 エフ.ホフマン−ラ ロシュ アーゲー 置換4−イミダゾール類
WO2008073125A1 (en) * 2006-12-12 2008-06-19 Chemagis Ltd. Moxonidine analogs, preparation processes and uses therefor
AU2007332641A1 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR)
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
NZ578260A (en) * 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
JP5130305B2 (ja) * 2007-02-15 2013-01-30 エフ.ホフマン−ラ ロシュ アーゲー Taar1リガンドとしての2−アミノオキサゾリン
EP2173720A2 (en) 2007-07-02 2010-04-14 F. Hoffmann-Roche AG 2-imidazolines having a good affinity to the trace amine associated receptors (taars)
EP2173719A1 (en) * 2007-07-03 2010-04-14 F. Hoffmann-Roche AG 4-imidazolines and their use as antidepressants
JP2010534701A (ja) * 2007-07-27 2010-11-11 エフ.ホフマン−ラ ロシュ アーゲー Taarリガンドとしての2−アゼチジンメタンアミン及び2−ピロリジンメタンアミン
KR20100039429A (ko) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 Cns 질환의 치료를 위한 벤즈아미드 유도체의 용도
JP5341084B2 (ja) * 2007-08-03 2013-11-13 エフ.ホフマン−ラ ロシュ アーゲー Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
AU2009273324A1 (en) * 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) * 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2586779A1 (en) 2011-10-24 2013-05-01 Hetero Research Foundation Process for the preparation of moxonidine
DE102012215896A1 (de) * 2012-09-07 2014-03-13 Wörwag Pharma GmbH & Co.KG Moxonidinsynthese mit Hilfe organischer Basen
ES2608004T3 (es) 2012-12-03 2017-04-05 WÖRWAG PHARMA GmbH & Co. KG Método mediante catálisis por transferencia de fase
EP2765131B1 (en) 2013-02-08 2016-11-23 Arevipharma GmbH Process for the production of Moxonidine
WO2014140034A1 (en) * 2013-03-14 2014-09-18 Farmak, A.S. Improved process for the manufacture of moxonidine
EP2829540A1 (en) 2013-07-26 2015-01-28 Abbott Healthcare Products B.V. Synthesis of substituted aminopyridines
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Taarのアゴニストとしての活性を有する5−エチル−4−メチル−ピラゾール−3−カルボキサミド誘導体
GB202103400D0 (en) * 2021-03-11 2021-04-28 3Z Ehf Novel treatments
US20240002369A1 (en) 2020-11-12 2024-01-04 3Z Ehf Novel treatments of attention deficit/hyperactivity disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines
GB1319840A (en) * 1970-08-27 1973-06-13 Beecham Group Ltd Substituted 5-amino imidazoles
BE795636A (fr) * 1972-02-19 1973-08-20 Schering Ag Nitroimidazolylpyrimidines, et leur procede de preparation
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
DE2220906A1 (de) * 1972-04-28 1973-11-15 Boehringer Sohn Ingelheim Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze sowie verfahren zu deren herstellung
BE503170A (da) * 1975-09-02

Also Published As

Publication number Publication date
GB2039275A (en) 1980-08-06
FR2441625A1 (fr) 1980-06-13
CH642965A5 (de) 1984-05-15
SE7909392L (sv) 1980-05-16
NL940011I2 (nl) 1998-05-06
NL7908192A (nl) 1980-05-19
NL190553B (nl) 1993-11-16
AT374197B (de) 1984-03-26
SE440079B (sv) 1985-07-15
IT7927284A0 (it) 1979-11-14
DK150142B (da) 1986-12-15
US4323570A (en) 1982-04-06
DK481879A (da) 1980-05-16
ATA727079A (de) 1983-08-15
DK150142C (da) 1987-06-01
AU541305B1 (en) 1985-01-03
CA1138454A (en) 1982-12-28
GB2039275B (en) 1982-11-17
IT1127225B (it) 1986-05-21
FR2441625B1 (da) 1981-12-31
ES486349A1 (es) 1980-06-16
NL940011I1 (nl) 1994-08-01

Similar Documents

Publication Publication Date Title
NL190553C (nl) Gesubstitueerde (2-imidazolin-2-yl)aminopirimidinen, alsmede farmaceutisch preparaat met antihypertensieve werking, dat een of meer van deze verbindingen bevat.
NL191540C (nl) Verbinding met antihypercholesteremische werkzaamheid, alsmede farmaceutisch preparaat dat deze verbinding bevat.
NL193457B (nl) Benzoheterocyclische verbindingen en farmaceutisch preparaat dat een dergelijke verbinding bevat.
NL980035I1 (nl) Benzimidazolen, de bereiding daarvan en deze verbindingen bevattende geneesmiddelen.
NL184364C (nl) Carbostyrilderivaten en zouten daarvan, alsmede gevormd farmaceutisch preparaat dat een of meer van dergelijke carbostyrilverbindingen bevat.
IT8019049A0 (it) Composti 2 penem, metodo per laloro preparazione e composizioni farmaceutiche contenenti tali composti.
NL190519C (nl) 4-Gesubstitueerde fenylazijnzuurverbindingen, alsmede farmaceutische preparaten.
DE3682711D1 (de) Als fungizide verwendbare heterocyclische verbindungen.
NL192343B (nl) 17Ó-gesubstitueerde androsta-(1,)4-(di)een-3-on-17ß-carbonzuurverbindingen met een ontstekingswerende werkzaamheid en farmaceutische preparaten, die deze verbindingen bevatten.
NL190781B (nl) N-acylfosfortriamiden, alsmede geneesmiddelen die N-acylfosfortriamiden bevatten.
NL189561C (nl) Gesubstitueerde cyclo-alkylideenmethylfenylazijnzuurverbindingen, alsmede een farmaceutisch preparaat, dat deze verbindingen bevat.
NL7902408A (nl) 3,7-digesubstitueerde-3-cefem-4-carbonzuurverbindingen en werkwijzen ter bereiding daarvan.
NL7804203A (nl) Chlooranilinederivaten met kalmerende werking, farma- ceutisch preparaat dat een dergelijke verbinding bevat alsmede werkwijzen ter bereiding van deze verbindingen.
NL194203B (nl) 1,4-dihydropyridineverbindingen en farmaceutisch preparaat dat ÚÚn of meer van deze bevat.
IT7926662A0 (it) Composizione farmaceutica contenente 3,4-di-idro-3-osso-2-chinossaline.
NL190485B (nl) Alfa-fluormethyl-alfa-aminoalkaanzuurderivaat, farmaceutisch preparaat dat een of meer zodanige verbindingen bevat, alsmede werkwijze voor het bereiden van de verbindingen.
NL7902726A (nl) Sulfonato-organosilanolverbindingen en preparaten, welke deze bevatten.
FI792597A7 (fi) Uusia N-fenyyli-indoliinijohdannaisia, niiden valmistus ja aineet, jotka sisältävät näitä yhdisteitä.
FI793445A7 (fi) Menetelmä uusien, aryylitrifluorietanolia sisältävien farmaseuttisten koostumusten valmivalmistamiseksi.
FI793776A7 (fi) 1,3,4- tiadiatsoli-2-karbonihappo- johdannaisia, menetelmä näiden yhdisteiden valmistamiseksi sekä näitä sisältäviä fungisidisia ja nematosidisia aineita.
NL189255C (nl) 2,4-dichloor-alfa-(n-imidazolylmethyl)-dibenzyletherderivaat, alsmede een deze verbinding omvattend farmaceutisch preparaat.
NL7808946A (nl) Beta-gesubstitueerde diketonen, alsmede preparaten die deze verbindingen bevatten.
NL193023B (nl) Indolylalkaanzuurderivaat, alsmede geneesmiddel met ontstekingsremmende werking.
NL7812144A (nl) 3-di-n-propyl-acetoxy-benzodiazepin-2-on-verbindingen, werkwijze voor de bereiding daarvan; spasmolytisch preparaat, dat een of meer van dergelijke verbindingen bevat.
NL187168C (nl) 3 beta-oxygesubstitueerde-18 beta-olean-30-carboxyderivaten, werkwijze ter bereiding daarvan en farmaceutische preparaten welke een of meer van deze verbindingen bevatten.

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: BEIERSDORF GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG

DNT Communications of changes of names of applicants whose applications have been laid open to public inspection

Free format text: BEIERSDORF-LILLY GMBH

AC1 Application for a supplementary protection certificate

Free format text: 940011, 940627

KC1 Grant of a supplementary protection certificate

Free format text: 940011, 19991108, EXPIRES: 20041107

V4 Discontinued because of reaching the maximum lifetime of a patent

Free format text: 19991108